Streetbeat News

Stock Prices

HUMA

Humacyte has entered into a securities purchase agreement with an institutional investor to sell $30 million worth of its common stock and warrants through a direct offering.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 12:01 pm

HALO

Halozyme Therapeutics (NASDAQ:HALO) has received mixed analyst ratings, with a majority being bullish. The average 12-month price target is $61.42, reflecting a 2.79% increase from the previous target. The company shows strong financial metrics but has a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 12:01 pm

SAVE

Spirit Airlines shares are declining due to reports that the company is considering filing for bankruptcy.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 12:00 pm

BENF

Beneficient's shares rose following the announcement that its subsidiary, Beneficient Company Holdings, completed a transaction to redesignate $126 million of preferred equity as non-redeemable.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 11:56 am

AAPL

AMD

AMKR

NVDA

SEMI

SHOC

TSM

Taiwan Semiconductor Manufacturing Co (TSMC) is advancing its 2nm technology development despite challenges. The company plans to commercialize 2nm technology by 2025 and is expanding its US operations, including a $65 billion investment in Arizona. TSMC's stock is up over 107% in the last year, but down 0.21% premarket.

Portfolio Pulse from Anusuya Lahiri

October 04, 2024 | 11:54 am

IPO

QCLN

RIVN

Rivian Automotive, Inc. (NASDAQ:RIVN) has lowered its annual production guidance due to a supply shortage, causing its shares to drop by 8.16%. The company now expects to produce 47,000 to 49,000 vehicles, down from 57,000. Despite this, Rivian reaffirms its delivery outlook. Investors can access Rivian through ETFs like Renaissance IPO ETF (NYSE:IPO) and First Trust NASDAQ Clean Edge Green Energy Index Fund (NASDAQ:QCLN).

Portfolio Pulse from Nabaparna Bhattacharya

October 04, 2024 | 11:52 am

IMRN

Trading for IMRN was temporarily halted and has now resumed. The halt was updated at 7:45 AM ET, indicating a resumption of trading following the dissemination of news.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 11:45 am

APOG

Apogee Enterprises shares rose following the release of strong Q2 financial results and an increase in FY25 adjusted EPS guidance.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 11:44 am

APOG

SMDV

Apogee Enterprises, Inc. (NASDAQ:APOG) exceeded Q2 expectations with sales of $342.4 million, surpassing the consensus estimate. Despite a 3.2% revenue dip, the company improved its gross margin and raised its FY25 EPS outlook. Apogee's shares rose 9.601% premarket. Investors can also access the stock via ProShares Russell 2000 Dividend Growers ETF (BATS:SMDV).

Portfolio Pulse from Lekha Gupta

October 04, 2024 | 11:44 am

LFCR

Lifecore Biomedical reported a Q1 EPS loss of $(0.53), missing the $(0.49) estimate, but sales of $24.70M beat the $23.19M estimate. EPS decreased by 29.27% from last year, while sales increased by 0.75%.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 11:37 am